Biologics and Cardiovascular Disease.

MedStar author(s):
Citation: Journal of Cardiovascular Pharmacology. 72(2):77-85, 2018 08.PMID: 29738370Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Anti-Inflammatory Agents/ad [Administration & Dosage] | *Biological Products/ad [Administration & Dosage] | *Cardiovascular Agents/ad [Administration & Dosage] | *Cardiovascular Diseases/dt [Drug Therapy] | *Cytokines/ai [Antagonists & Inhibitors] | *Inflammation Mediators/ai [Antagonists & Inhibitors] | Animals | Anti-Inflammatory Agents/ae [Adverse Effects] | Biological Products/ae [Adverse Effects] | Cardiotoxicity | Cardiovascular Agents/ae [Adverse Effects] | Cardiovascular Diseases/ge [Genetics] | Cardiovascular Diseases/im [Immunology] | Cardiovascular Diseases/me [Metabolism] | Cytokines/im [Immunology] | Cytokines/me [Metabolism] | Humans | Inflammation Mediators/im [Immunology] | Inflammation Mediators/me [Metabolism] | Liposomes | Proprotein Convertase 9/ge [Genetics] | RNA, Small Interfering/tu [Therapeutic Use] | RNAi Therapeutics/mt [Methods] | Signal Transduction/de [Drug Effects] | Treatment OutcomeYear: 2018Local holdings: Available online from MWHC library: 1996 - presentISSN:
  • 0160-2446
Name of journal: Journal of cardiovascular pharmacologyAbstract: The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations. Atherosclerosis, myocardial infarction, and heart failure have been closely linked to the inflammatory response. Accordingly, cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 have been targeted. Non-inflammatory mediators, such as proprotein convertase subtilisin kexin type 9 (PCSK9), have been selected for therapeutic intervention as well. Furthermore, RNA interference (RNAi) therapy has emerged and may serve as another targeted therapeutic mechanism. Herein, we will review the history, obstacles, and advances in utilizing biologic therapy for CVD.All authors: Albelda MT, Frias JC, Lipinski MJ, Van Taunay JSFiscal year: FY2019Fiscal year of original publication: FY2018Digital Object Identifier: Date added to catalog: 2018-06-19
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29738370 Available 29738370

Available online from MWHC library: 1996 - present

The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations. Atherosclerosis, myocardial infarction, and heart failure have been closely linked to the inflammatory response. Accordingly, cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 have been targeted. Non-inflammatory mediators, such as proprotein convertase subtilisin kexin type 9 (PCSK9), have been selected for therapeutic intervention as well. Furthermore, RNA interference (RNAi) therapy has emerged and may serve as another targeted therapeutic mechanism. Herein, we will review the history, obstacles, and advances in utilizing biologic therapy for CVD.

English

Powered by Koha